Search

Your search keyword '"Salam Zakko"' showing total 3 results
Start Over Author "Salam Zakko" Journal alimentary pharmacology & therapeutics
3 results on '"Salam Zakko"'

1. Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence

Author

Nicholas J. Talley, János Banai, Juris Pokrotnieks, M. M. Diez Alonso, Rifaat Safadi, J. Derova, Zsolt Tulassay, I. Bunganic, J. Kondrackiene, T. Vich, Salam Zakko, J. Mäkelä, Ralf Mohrbacher, Karin Dilger, Wolfgang Kruis, D. Tuculanu, N. Ferreira, Roland Greinwald, Austin Curtin, Milan Lukas, S. Björck, T. Eisenbach, Andrey E. Dorofeyev, Vassilios Kardalinos, and Robin C. Spiller

Subjects
Male, medicine.medical_specialty, Randomised Clinical Trial, Placebo, Gastroenterology, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Double-Blind Method, Mesalazine, Randomized controlled trial, Recurrence, law, Internal medicine, parasitic diseases, medicine, Clinical endpoint, Humans, Pharmacology (medical), In patient, Mesalamine, Adverse effect, Diverticulitis, Hepatology, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Middle Aged, medicine.disease, Surgery, Clinical trial, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, business
Abstract

SummaryBackground Previous studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis. Aim To investigate the efficacy and safety of mesalazine granules in the prevention of recurrence of diverticulitis after acute uncomplicated diverticulitis. Methods Two phase 3, randomised, placebo-controlled, double-blind multicentre trials (SAG-37 and SAG-51) investigated mesalazine granules in patients with prior episodes (1 episode. Safety data revealed no new adverse events. Conclusion Mesalazine was not superior to placebo in preventing recurrence of diverticulitis.

Published
2017

2. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials

Author

G. L. Gordon, Kunal Merchant, S. Sedghi, Uma K. Murthy, Salam Zakko, Gary R. Lichtenstein, William P. Forbes, Enoch Bortey, and Ronald E. Pruitt

Subjects
Adult, medicine.medical_specialty, Kaplan-Meier Estimate, Placebo, Severity of Illness Index, Gastroenterology, Drug Administration Schedule, law.invention, chemistry.chemical_compound, Double-Blind Method, Randomized controlled trial, Maintenance therapy, Mesalazine, law, Internal medicine, Severity of illness, medicine, Clinical endpoint, Humans, Pharmacology (medical), Colitis, Mesalamine, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Hepatology, Drug Substitution, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Middle Aged, medicine.disease, Ulcerative colitis, Surgery, Treatment Outcome, chemistry, Colitis, Ulcerative, business
Abstract

Summary Background Mesalazine (mesalamine) granules (MG) were shown to be effective for the maintenance of remission of ulcerative colitis (UC) in two double-blind placebo-controlled trials. Aim To evaluate the efficacy of once-daily MG for maintenance of remission in patients with UC who switched from other 5-aminosalicylic acid (5-ASA) formulations. Methods Data from two independent multicenter, randomised, double-blind, placebo-controlled, 6-month trials evaluating patients with UC in remission were combined for analysis of a subpopulation of patients who switched from other 5-ASA formulations to MG 1.5 g or placebo upon randomisation. The primary endpoint was the percentage of patients who remained relapse-free at Month 6 or end of treatment. Relapse was defined as a Sutherland Disease Activity Index (SDAI) rectal bleeding score ≥1 and mucosal appearance score ≥2, a UC flare or medication used to treat a UC flare. Results Of the 487 patients who received 5-ASA maintenance therapy at enrolment, 322 were in the MG group and 165 were in the placebo group. The percentage of patients who remained relapse-free (based on Sutherland Disease Activity Index scores) after 6 months was significantly higher with MG than placebo (78.3% vs. 58.8%, P

Published
2012

3. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial

Author

Uma K. Murthy, G. L. Gordon, Audrey L. Shaw, Enoch Bortey, Ronald E. Pruitt, Gary R. Lichtenstein, S. Sedghi, William P. Forbes, Kunal Merchant, and Salam Zakko

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Placebo-controlled study, medicine.disease, Placebo, Ulcerative colitis, law.invention, Surgery, Clinical trial, chemistry.chemical_compound, Mesalazine, chemistry, Randomized controlled trial, law, Internal medicine, Medicine, Pharmacology (medical), Colitis, Adverse effect, business
Abstract

Aliment Pharmacol Ther 2010; 32: 990–999 Summary Background Ulcerative colitis (UC) is a chronic relapsing and remitting idiopathic inflammatory bowel disorder. Aim To evaluate once-daily mesalamine (mesalazine) granules (MG) for maintenance of remission of UC. Methods Randomized, double-blind, placebo-controlled trial of patients (n = 209 MG, n = 96 placebo) with UC in remission [revised Sutherland Disease Activity Index (SDAI) rectal bleeding = 0, mucosal appearance

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results